Elixir, the pharmacy benefit manager formerly known as EnvisionRxOptions, rebranded under the Elixir name in September 2020. Under Elixir's own Pharmacy Manual, a pharmacy audited by Elixir gets thirty calendar days to respond to the audit request and, if the audit turns up discrepancies, another thirty days to appeal before a final decision issues. Elixir's Network Compliance Committee also holds the authority to suspend a pharmacy's network participation while the underlying audit is still open, on just fifteen calendar days' notice to appeal the suspension itself. For an independent pharmacy that depends on Elixir claims volume, that suspension power can cut off reimbursement before the audit that triggered it has even been resolved.
Elixir's Audit Types and Documentation Demands
Elixir conducts three types of PBM audit: desk, onsite, and investigational. Desk audits are generated by proprietary algorithms flagging pharmacy claims data and are communicated by email or fax. Onsite audits occur at the pharmacy's physical location; Elixir generally provides advance notice by mail, though the manual does not require it. Investigational audits carry a broader scope and shorter deadlines, typically triggered by a Plan Sponsor request, a CMS request, or a member complaint. Across all three categories, Elixir can demand prescription hard copies, dispensing labels, signature logs or proof of delivery, compound logs, and manufacturer, wholesaler, and distributor invoices submitted directly from the wholesaler. Extension requests must reach Elixir's audit department in writing at least three days before the response deadline, and Elixir grants them solely at its own discretion.
The Discrepancy Letter and a Single Appeal Opportunity
If Elixir's review turns up a discrepancy, it sends the pharmacy a discrepancy letter with a table describing each finding and the documentation Elixir will accept to rebut it. The pharmacy has thirty days from that letter to submit its audit appeal, and the manual allows only one attempt. Appeal documents that arrive after the deadline are excluded from review regardless of the underlying merits. A pharmacy that never responded to the original audit request can still file an appeal by the discrepancy-letter deadline, but a pharmacy that stays silent through both the audit-response window and the appeal window forfeits the right to contest the findings at all.
Suspension Can Run Ahead of a Final Audit Finding
Separate from the audit-appeal process, Elixir's Network Compliance Committee can suspend a pharmacy's network participation for reasons that include, but are not limited to, audit results. Firms that track PBM notices have observed Elixir issuing suspension notices before the pharmacy receives final audit results or any opportunity to appeal the underlying finding. A pharmacy has only fifteen calendar days to appeal a suspension or termination notice, the NCC reviews appeals once a month, and the manual allows a single appeal attempt. Pharmacies typically remain suspended for up to six months while the NCC decides whether to reinstate the pharmacy or move to network termination, and the appeal process is unavailable to pharmacies already terminated or under investigation for suspected fraud, including inventory shortages.
Missed Notices Widen the Recoupment Exposure
Elixir's manual places the burden of receipt on the pharmacy. According to PAAS National, a pharmacy audit assistance service, a pharmacy that never actually received an Elixir audit notice can still be logged as a non-response. Elixir then recoups funds across every fill date tied to the flagged prescription numbers rather than the single fill date originally targeted, illustrating what a PBM audit really costs once a pharmacy is marked as a non-response. That expanded recoupment exposure accrues before the pharmacy has said a word in its own defense.
Elixir's fifteen-day suspension appeal window and its thirty-day audit appeal window do not pause for a missed notice. Both deadlines run whether or not the pharmacy actually received it.
Why Early Legal Counsel Is Critical
It is critical that pharmacies promptly retain experienced healthcare defense counsel upon receiving an Elixir audit request, discrepancy letter, or suspension notice. Early legal intervention can protect the pharmacy's appeal rights, ensure the audit response is complete and consistent with Elixir's documentation standards, avoid admissions that undercut a later appeal, and allow counsel to communicate with Elixir's audit department on the pharmacy's behalf. A pharmacy already contesting findings from another PBM, such as a Prime Therapeutics audit, benefits from the same early involvement, since a missed deadline forecloses the pharmacy's only opportunity to contest a finding or a suspension.
How Health Law Alliance Can Help
Health Law Alliance represents pharmacies nationwide in Elixir audits, discrepancy appeals, and network suspension and termination matters, as part of the firm's PBM audit defense practice. If your pharmacy has received an Elixir audit request, discrepancy letter, or suspension notice, contact us for a free, confidential consultation.
